Based on ratings from 3 stock analysts, the Establishment Labs Holdings Inc stock price is expected to increase by 55.98% in 12 months. This is calculated by using the average 12-month stock price forecast for Establishment Labs Holdings Inc. The lowest target is $46 and the highest is $75. Please note analyst price targets are not guaranteed and could be missed completely.
ESTA is a stock in Healthcare which has been forecasted to be worth $61.33 as an average. On the higher end, the forecast price is $75 USD by Allen Gong from JP Morgan and on the lower end ESTA is forecasted to be $46 by from .
These are the latest 20 analyst ratings of ESTA.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Marie Thibault BTIG | Buy | $65 | Maintains | Oct 14, 2024 |
Joanne Wuensch Citigroup | Neutral | $50 | Maintains | Oct 1, 2024 |
Joanne Wuensch Citigroup | Neutral | $45 | Maintains | Aug 22, 2024 |
George Sellers Stephens & Co. | Overweight | $68 | Reiterates | Aug 7, 2024 |
Allen Gong JP Morgan | Overweight | $50 | Maintains | Aug 7, 2024 |
Citigroup | Neutral | Maintains | Jul 11, 2024 | |
Joanne Wuensch Citigroup | Neutral | $50 | Maintains | Jul 10, 2024 |
Anthony Petrone Mizuho | Buy | $70 | Maintains | Jun 6, 2024 |
Joanne Wuensch Citigroup | Neutral | $60 | Downgrade | May 22, 2024 |
Joanne Wuensch Citigroup | Buy | $60 | Maintains | Apr 3, 2024 |
Anthony Petrone Mizuho | Buy | $65 | Reiterates | Apr 1, 2024 |
Joshua Jennings TD Cowen | Outperform | $60 | Maintains | Mar 12, 2024 |
Allen Gong JP Morgan | Overweight | $53 | Maintains | Feb 29, 2024 |
George Sellers Stephens & Co. | Overweight | $47 | Reiterates | Jan 11, 2024 |
Neil Chatterji B. Riley Securities | Buy | $50 | Maintains | Nov 9, 2023 |
Anthony Petrone Mizuho | Buy | $50 | Maintains | Nov 8, 2023 |
TD Cowen | Outperform | Maintains | Nov 8, 2023 | |
Allen Gong JP Morgan | Overweight | $75 | Initiates | Aug 31, 2023 |
Stephens & Co. | Overweight | Reiterates | Jul 21, 2023 | |
Joanne Wuensch Citigroup | Buy | $79 | Initiates | Jun 29, 2023 |
When did it IPO
2018
Staff Count
857
Country
Costa Rica
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Juan Jose Chacon Quiros
Market Cap
$1.18B
In 2023, ESTA generated $165.2M in revenue, which was a increase of 2.13% from the previous year. This can be seen as a signal that ESTA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in the 2024 UBS Global Healthcare Conference from November 11-14, featuring CEO Juan Josรฉ Chacรณn-Quirรณs and CFO Raj Denhoy.
Why It Matters - Participation in key investment conferences can enhance visibility and credibility for Establishment Labs, potentially attracting investors and driving stock performance.
Summary - Establishment Labs Holdings Inc. (NASDAQ: ESTA) held its Q3 2024 earnings call on November 7, 2024, with key executives discussing company performance and future outlook.
Why It Matters - The earnings call details provide insights into Establishment Labs' financial health and performance, influencing stock valuation and investor sentiment.
Summary - Establishment Labs Holdings Inc. reported Q3 2024 revenue of $40.2 million and updated its 2024 revenue guidance to $165-$168 million, down from $174-$184 million.
Why It Matters - Establishment Labs' revenue guidance cut indicates potential challenges ahead, which may affect stock performance and investor sentiment regarding future growth prospects.
Summary - Establishment Labs (ESTA) reported a quarterly loss of $0.59 per share, better than the expected loss of $0.61, and an improvement from a loss of $1.12 per share a year prior.
Why It Matters - Establishment Labs' smaller quarterly loss than expected suggests improving financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Summary - Establishment Labs Holdings Inc. has entered a securities purchase agreement for 765,696 common shares and pre-funded warrants for an additional 328,161 shares in a registered direct offering.
Why It Matters - The securities purchase agreement indicates capital raising efforts, which may impact share dilution and financial stability, influencing investor sentiment and stock performance.
Summary - Establishment Labs Holdings (NASDAQ: ESTA) presented three-year clinical results for Mia Femtechโข at the World Symposium on Ergonomic Implants in Barcelona, focusing on women's health in breast aesthetics and reconstruction.
Why It Matters - The presentation of positive three-year clinical results for Mia Femtechโข could enhance investor confidence in Establishment Labs' growth potential and market position in women's health.